Results 201 to 210 of about 351,828 (261)
Antibody–drug conjugates (ADCs) transform breast cancer therapy, yet resistance limits their durability. Emerging evidence reveals that ADC failure is not solely tumor‐intrinsic but shaped by dynamic tumor–microenvironment interactions that alter drug delivery, processing, and response.
Minji Seo, Jangsoon Lee, Naoto T. Ueno
wiley +1 more source
The functional schematic diagram of tumor associated neutrophils. Abstract Enhancing cervical cancer (CC) immunotherapy requires deciphering the heterogeneous tumor immune microenvironment (TIME), particularly neutrophil phenotypic dynamics. Here, 1) we collected 543 CC cases to find that patients with elevated neutrophil levels have a higher incidence
Xingyu Chang +7 more
wiley +1 more source
A real‐world model of structured animal product restriction practiced for religious reasons reveals the dynamic adaptability of the human gut microbiome to dietary change and uncovers reductions in diversity and rare taxa loss. Integrated microbiome, metabolomic, and proteomic analyses uncover coordinated taxonomic and molecular shifts and identify ...
Christina Emmanouil +7 more
wiley +1 more source
3D Bioprinted Fat‐Myocardium Model Unravels the Role of Adipocyte Hypertrophy in Atrial Dysfunction
A human‐derived 3D bioprinted fat–myocardium model is developed to investigate how adipocyte hypertrophy drives atrial dysfunction in obesity. Palmitate‐induced adipocyte hypertrophy promotes adipose dysfunction that impairs atrial cardiomyocyte metabolism and electrophysiology through both paracrine and direct interactions. This platform recapitulates
Lara Ece Celebi, Pinar Zorlutuna
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
International Journal of Clinical Oncology, 2007
In spite of clinical practice guidelines such as the National Cancer Institute (NCI)-Physician Data Query (PDQ), in which primary androgen deprivation therapy (PADT) is not recommended at all as the primary treatment for localized prostate cancer, many such patients have actually been treated with PADT in Japan.
Mikio, Namiki +6 more
openaire +2 more sources
In spite of clinical practice guidelines such as the National Cancer Institute (NCI)-Physician Data Query (PDQ), in which primary androgen deprivation therapy (PADT) is not recommended at all as the primary treatment for localized prostate cancer, many such patients have actually been treated with PADT in Japan.
Mikio, Namiki +6 more
openaire +2 more sources
The Indian Journal of Pediatrics, 2005
Growth hormone (GH) therapy has revolutionized treatment of children with growth hormone deficiency (GHD). Improved height outcome with final height in the target height range has been achieved in these children. Identification of Creutzfeldt-Jakob disease, a deadly prion mediated disorder, in recipients of pituitary GH accelerated the transition from ...
Anurag, Bajpai, P Sn, Menon
openaire +2 more sources
Growth hormone (GH) therapy has revolutionized treatment of children with growth hormone deficiency (GHD). Improved height outcome with final height in the target height range has been achieved in these children. Identification of Creutzfeldt-Jakob disease, a deadly prion mediated disorder, in recipients of pituitary GH accelerated the transition from ...
Anurag, Bajpai, P Sn, Menon
openaire +2 more sources
Breast Cancer, 2002
Recently, the guidelines for adjuvant hormonal therapy for primary breast cancer were presented at the National Institute of Health Consensus Development Conference in November 2000 and at the 7th International Conference on Adjuvant Therapy of Primary Breast Cancer in February 2001. Adjuvant hormonal therapy should be offered basically to all patients
Yasuhiro, Tamaki +2 more
openaire +2 more sources
Recently, the guidelines for adjuvant hormonal therapy for primary breast cancer were presented at the National Institute of Health Consensus Development Conference in November 2000 and at the 7th International Conference on Adjuvant Therapy of Primary Breast Cancer in February 2001. Adjuvant hormonal therapy should be offered basically to all patients
Yasuhiro, Tamaki +2 more
openaire +2 more sources
The Nurse Practitioner, 1996
More than 40 million women in the United States are now going through or are past menopause. Another 3.5 million or more will reach midlife in the next decade. As their life expectancy increases (mean life expectancy of women is now approximately 84 years), so does the need for therapeutic regimens related to reproductive function and aging in woman ...
openaire +4 more sources
More than 40 million women in the United States are now going through or are past menopause. Another 3.5 million or more will reach midlife in the next decade. As their life expectancy increases (mean life expectancy of women is now approximately 84 years), so does the need for therapeutic regimens related to reproductive function and aging in woman ...
openaire +4 more sources
Current Opinion in Chemical Biology, 1999
Hormone replacement therapy is increasingly being used for purposes unrelated to the alleviation of menopausal symptoms, such as the prevention of osteoporosis and cardiovascular disease. Clinical trials, however, suggest that the one drug/many purposes concept may be too optimistic.
T, Kooistra, J J, Emeis
openaire +2 more sources
Hormone replacement therapy is increasingly being used for purposes unrelated to the alleviation of menopausal symptoms, such as the prevention of osteoporosis and cardiovascular disease. Clinical trials, however, suggest that the one drug/many purposes concept may be too optimistic.
T, Kooistra, J J, Emeis
openaire +2 more sources
Journal of Obstetrics and Gynaecology Canada, 2005
Although estrogen has been clinically available for more than 6 decades, women have been confused by different opinions regarding the risks and benefits of menopausal hormone therapy (HT), estrogen therapy (ET), and estrogen-progestin therapy (EPT).
Bhagu R, Bhavnani, Ronald C, Strickler
openaire +2 more sources
Although estrogen has been clinically available for more than 6 decades, women have been confused by different opinions regarding the risks and benefits of menopausal hormone therapy (HT), estrogen therapy (ET), and estrogen-progestin therapy (EPT).
Bhagu R, Bhavnani, Ronald C, Strickler
openaire +2 more sources

